Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1985 1
1987 1
1988 4
1989 6
1990 2
1991 2
1992 2
1993 4
1994 5
1995 5
1996 4
1997 1
1998 2
1999 1
2000 4
2001 3
2002 3
2003 8
2004 11
2005 12
2006 4
2007 4
2008 13
2009 10
2010 6
2011 5
2012 8
2013 9
2014 14
2015 13
2016 9
2017 3
2018 7
2019 4
2020 1
2021 4
2022 10
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Results by year

Filters applied: . Clear all
Page 1
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
Diabetic Retinopathy Clinical Research Network; Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Diabetic Retinopathy Clinical Research Network, et al. N Engl J Med. 2015 Mar 26;372(13):1193-203. doi: 10.1056/NEJMoa1414264. Epub 2015 Feb 18. N Engl J Med. 2015. PMID: 25692915 Free PMC article. Clinical Trial.
Reply.
Bressler SB, Beaulieu WT, Glassman AR. Bressler SB, et al. Ophthalmology. 2017 Dec;124(12):e88-e89. doi: 10.1016/j.ophtha.2017.06.026. Ophthalmology. 2017. PMID: 29157436 No abstract available.
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW; Diabetic Retinopathy Clinical Research Network. Wells JA, et al. Among authors: bressler sb. Ophthalmology. 2016 Jun;123(6):1351-9. doi: 10.1016/j.ophtha.2016.02.022. Epub 2016 Feb 27. Ophthalmology. 2016. PMID: 26935357 Free PMC article. Clinical Trial.
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.
Jhaveri CD, Glassman AR, Ferris FL 3rd, Liu D, Maguire MG, Allen JB, Baker CW, Browning D, Cunningham MA, Friedman SM, Jampol LM, Marcus DM, Martin DF, Preston CM, Stockdale CR, Sun JK; DRCR Retina Network. Jhaveri CD, et al. N Engl J Med. 2022 Aug 25;387(8):692-703. doi: 10.1056/NEJMoa2204225. Epub 2022 Jul 14. N Engl J Med. 2022. PMID: 35833805 Free PMC article. Clinical Trial.
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, Melia M, Wells JA 3rd; Diabetic Retinopathy Clinical Research Network. Bressler NM, et al. Among authors: bressler sb. JAMA Ophthalmol. 2018 Mar 1;136(3):257-269. doi: 10.1001/jamaophthalmol.2017.6565. JAMA Ophthalmol. 2018. PMID: 29392288 Free PMC article. Clinical Trial.
Severe Intraocular Inflammation Following Intravitreal Faricimab.
Thangamathesvaran L, Kong J, Bressler SB, Singh M, Wenick AS, Scott AW, Arévalo JF, Bressler NM. Thangamathesvaran L, et al. Among authors: bressler sb. JAMA Ophthalmol. 2024 Apr 1;142(4):365-370. doi: 10.1001/jamaophthalmol.2024.0530. JAMA Ophthalmol. 2024. PMID: 38421861
Age-related macular degeneration.
Bressler NM, Bressler SB, Fine SL. Bressler NM, et al. Among authors: bressler sb. Surv Ophthalmol. 1988 May-Jun;32(6):375-413. doi: 10.1016/0039-6257(88)90052-5. Surv Ophthalmol. 1988. PMID: 2457955 Free article. Review.
195 results